Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 222

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 222
---
,674
    )

    1,723

    (1,829
    )

    Operating lease liabilities

    241

    837

    2,969

    Accounts payable

    3,342

    235

    (389
    )

    Accrued expenses

    (2,501
    )

    2,632

    (1,319
    )

    Net cash used in operating activities

    (51,282
    )

    (55,657
    )

    (63,760
    )

    Cash flows from investing activities:

    Purchases of property and equipment

    (655
    )

    (962
    )

    (7,984
    )

    Proceeds from sale of property and equipment

    251

    —

    —

    Purchases of marketable securities

    (148,286
    )

    (220,539
    )

    (229,199
    )

    Maturities of marketable securities

    202,042

    170,956

    235,815

    Net cash provided by investing activities

    53,352

    (50,545
    )

    (1,368
    )

    Cash flows from financing activities:

    Issuance of common stock, net of issuance costs

    —

    35,121

    —

    Proceeds from the exercise of stock options and common stock    issued under the 2020 ESPP

    313

    456

    958

    Net cash provided by financing activities

    313

    35,577

    958

    Impact of exchange rates on cash, cash equivalents, and restricted cash

    (35
    )

    34

    —

    Net increase (decrease) in cash, cash equivalents, and restricted cash

    2,348

    (70,591
    )

    (64,170
    )

    Cash, cash equivalents, and restricted cash

    Cash, cash equivalents, and restricted cash - beginning of period

    38,528

    109,119

    173,289

    Cash, cash equivalents, and restricted cash - end of period
     
    $
    40,876

    $
    38,528

    109,119

    Supplemental disclosures of noncash investing activities

    Accrued purchases of property and